CurrentCignaPolicy 0103

Gastric electrical stimulation (GES) for gastroparesis

Defines medical coverage for permanent and temporary gastric electrical stimulation devices for treating intractable nausea and vomiting secondary to gastroparesis for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyGastric electrical stimulation (GES) for gastroparesis

Policy CodePolicy 0103

Change TypeAnnual reviewprior policy statement revision noted

Effective Date

Next Review DateDec 15, 2024

Key ActionObtain prior authorization and document that Enterra Therapy meets FDA HDE specifications and that medical therapy failed, was contraindicated, or intolerable.

SourceLink

POLICY UPDATE CHANGES

No clinical policy statement changes during the most recent annual review.

Revised the gastric electrical stimulation (GES) or gastric pacing for any other indication policy statement.

HDEHDE indication

Not coveredTemporary GES

≤12 moFollow-up reported

190SHAPE trial participants

H990014

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Permanent GES (Enterra) coverage criteria

Covered when ALL of the following are met:

HDE-specified indication: Device is used in accordance with FDA Humanitarian Device Exemption (HDE) specifications for Enterra Therapy for chronic, intractable (drug‑refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology

Supports HDE indication per FDA (Enterra Therapy received HDE March 31, 2000).

Failure of medical therapy: Symptoms are refractory with failure, contraindication, or intolerance to pharmaceutical therapy (prokinetic and antiemetic agents) and dietary management

Primary management includes dietary modification and pharmacologic therapy prior to considering GES.

Appropriate patient population: Patient is an adult meeting HDE-defined age considerations (device not evaluated for patients <18 or >70 years)

Per FDA labeling: Enterra system not evaluated under age 18 or over age 70.

Not covered / Experimental

Not covered or considered experimental when ANY of the following apply:

Non‑HDE indications: GES or gastric pacing used for any indication other than intractable nausea and vomiting secondary to gastroparesis per the FDA HDE (eg, obesity, type 2 diabetes mellitus, other investigational uses)

GES or gastric pacing for any other indication is not covered or reimbursable.

Temporary GES (tGES): Temporary gastric electrical stimulation (tGES) or percutaneous/endoscopic temporary stimulation is considered experimental, investigational, or unproven and is not covered

Temporary leads/external systems represent off‑label use and lack FDA approval for temporary GES.

GES for Obesity or Type 2 Diabetes Mellitus (Not Covered / Investigational)

Coverage stance for non‑gastroparesis indications:

GES for obesity or T2DM (Investigational): Use of gastric electrical stimulation for morbid obesity or for treatment of type 2 diabetes mellitus is considered investigational/unproven and not covered due to insufficient evidence regarding mechanism, stimulation parameters, patient selection, and long‑term effectiveness

Supported by systematic reviews, RCTs and small case series with inconsistent or transient effects and short follow‑up; devices (eg, Transcend/Exilis, DIAMOND/TANTALUS) remain investigational for these indications.

GES for Refractory Gastroparesis (Covered when criteria met)

Separate covered indication:

GES for intractable nausea and vomiting secondary to gastroparesis: GES implantation (codes 43647, 43881, 64590, 95980‑95982) is considered medically necessary when the applicable policy statement criteria for refractory gastroparesis are met

Coding listed here for contrast with non‑covered indications; detailed gastroparesis coverage criteria are in other policy sections.

Policy review and device approval references

Policy review and device approval references: Policy references Enterra Therapy FDA approval (H990014) and documents annual review status

Enterra Therapy HDE approval (FDA H990014); annual review documented with no clinical policy statement changes on 12/15/2024 and prior revision on 10/15/2023.

GES for indications other than intractable nausea and vomiting secondary to gastroparesis is investigational and not covered under this policy. The policy explicitly states that "Gastric electrical stimulation (GES) or gastric pacing for any other indication is not covered or reimbursable," including investigational uses being evaluated for obesity and type 2 diabetes mellitus.

Implantation of GES or use of temporary stimulation specifically for morbid obesity (including procedures targeting the lesser curvature) is considered experimental/investigational and not reimbursable. The policy notes the Transcend/IGS systems and identifies unresolved issues (mechanism, stimulation parameters, patient selection) and insufficient evidence to support gastric pacing for morbid obesity; unlisted stomach procedure codes (e.g., 43659, 43999) used for these indications are not covered.

This document fragment does not list discrete exclusion conditions beyond the general statements in the coverage section; refer to other parts of the policy for a complete exclusions list and any plan‑specific limitations.

Temporary gastric electrical stimulation (tGES), including endoscopic or percutaneous lead techniques and use of external temporary leads, is considered experimental, investigational, or unproven and is not medically necessary. The FDA has not approved temporary GES devices for this indication and use of temporary external leads represents an off‑label application.

There is insufficient evidence to support use of gastric pacing or gastric electrical stimulation for morbid obesity. Case series are small with short follow‑up, randomized trials and systematic reviews show inconsistent or transient benefits, and important uncertainties remain regarding mechanism, optimal stimulation patterns, electrode placement, patient selection, and long‑term effectiveness; therefore these uses are considered not medically necessary / investigational.

Within the cited fragments, no additional explicit 'not medically necessary' statements beyond the general investigational and non‑covered language are provided; see the full policy for any further not‑medically‑necessary determinations.

Coding

Covered codes when criteria for gastroparesis are metCPTCovered

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling.
95980	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming.
95981	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming.
95982	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming.

Not covered for morbid obesity / other indicationsCPTNot Covered

43659	Unlisted laparoscopy procedure, stomach.
43999	Unlisted procedure, stomach.

Referenced device approval identifier (Enterra HDE)mixed

H990014

Enterra Therapy System — FDA Humanitarian Device Exemption identifier

Provider Actions / Billing

Prior Authorization

Prior Authorization Required for Permanent GES

Prior authorization is required for permanent gastric electrical stimulation (GES) devices (e.g., Enterra Therapy) when the Humanitarian Device Exemption (HDE) criteria are met for intractable nausea and vomiting secondary to gastroparesis after failure, contraindication, or intolerance of pharmaceutical therapy. Include documentation demonstrating prior medical therapy failure (dietary modification and pharmacologic therapy such as prokinetic and antiemetic agents) and rationale for selecting permanent GES.

Enterra Therapy (HDE H990014) — prior authorization required for permanent implantation when HDE criteria met
Document failure, contraindication, or intolerance to pharmaceutical therapy (e.g., metoclopramide, erythromycin) and dietary management prior to approval

Billing Rule

Prior Authorization and Coding Requirements

Background

Gastroparesis is a chronic gastric motility disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, commonly presenting with early satiety, nausea, vomiting, bloating, and abdominal discomfort. Etiologies include idiopathic, diabetic, medication‑induced (iatrogenic), and postsurgical causes. Initial management focuses on dietary modification and pharmacologic therapy (prokinetics and antiemetics); GES is considered for patients with persistent, drug‑refractory symptoms.

Definitions

High-frequency/low-energy GES (Enterra Therapy) — key characteristics of the device

TypeHigh-frequency, low-energy gastric electrical stimulation (short pulse stimulation)

Typical stimulation parametersHigh-frequency at ~12 cycles per minute (about 4x basal rate) using short pulses

ImplantationImplanted device with intramuscular leads and implanted pulse generator (intended for permanent implantation)

Primary intended effectReduce symptoms of gastroparesis (intractable nausea and vomiting) and may improve gastric emptying

Regulatory/clinical contextExample device: Enterra Therapy — classified as high-frequency/low-energy GES

Low-frequency/high-energy GES (gastric pacing) — definition and distinction from Enterra

Policy Summary

PayerCigna

PolicyGastric electrical stimulation (GES) for gastroparesis

Policy CodePolicy 0103

Change TypeAnnual reviewprior policy statement revision noted

Effective Date

Next Review DateDec 15, 2024

Key ActionObtain prior authorization and document that Enterra Therapy meets FDA HDE specifications and that medical therapy failed, was contraindicated, or intolerable.

SourceLink

On This Page

Submit prior authorization requests for implantation procedures using the appropriate covered procedure codes and include supporting clinical documentation. Claims submitted without covered codes under this policy may be denied as not covered.

Covered procedure codes for implantation/replacement when medically necessary: 43647, 43881, 64590, 95980, 95981, 95982
Unlisted procedure codes that may be used for other or unspecified stomach procedures: 43659, 43999 — review clinical justification before submission

Prior Authorization

Enterra Therapy — Prior Authorization and Documentation

Prior authorization is required specifically for Enterra Therapy permanent implantation. Reference the FDA HDE approval and include device-specific documentation (approval order or summary) and patient age considerations (Enterra HDE not evaluated for <18 or >70 years).

Include FDA HDE reference: Enterra Therapy System, H990014 (Approval Order and Summary of Safety and Probable Benefit).
Document patient age and that indication is chronic, intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Denial Risk

Experimental/Investigational Use for Other Indications

GES for indications other than intractable nausea and vomiting due to gastroparesis (per HDE) is considered experimental, investigational, or unproven and is not covered or reimbursable. Temporary GES is considered experimental/investigational/unproven.

GES for morbid obesity, other weight-loss indications, or non-gastroparesis indications — Experimental/Investigational/Unproven (not covered)
Temporary GES — Experimental/Investigational/Unproven (not covered)
Open or laparoscopic implantation/replacement of gastric stimulation electrodes for non-gastroparesis indications (e.g., lesser curvature for morbid obesity) — not covered (codes 43659, 43999)

Documentation Required

Coding and Documentation Requirements

Ensure all claims are submitted with the most appropriate current codes and include supporting clinical documentation to substantiate medical necessity. Failure to include required documentation or using non-covered codes may result in denial.

Attach clinical notes, prior therapy records, and device-specific documentation with the authorization request and claim submission
Claims for services without covered code(s) under this policy will be denied as not covered

Documentation Required

Documentation for Gastroparesis Indication

Document that the patient has failed, has a contraindication to, or is intolerant of medical therapy (dietary and pharmacologic) prior to considering permanent GES. Provide details of therapies tried, durations, and responses.

Record trials of dietary modification and specific pharmacologic therapies (e.g., metoclopramide, erythromycin, antiemetics) and outcomes
Include prior interventions such as enteral feeding or TPN if used for refractory cases

Step Therapy

Step therapy requirements: none specified for GES in this policy. Providers should still document prior medical therapy attempts as outlined above.

No formal step therapy program is specified in this policy for GES

DefinitionLow-frequency, high-energy gastric electrical stimulation (gastric pacing) uses long pulse stimulation at frequencies close to the normal gastric slow wave to attempt to reset slow wave rhythm

Stimulation characteristicsFrequencies close to or above the normal slow-wave cycle with long pulse duration

Implantation/suitabilityInvolves heavy batteries and is generally not suitable for permanent implantation as described in the literature

Clinical effect and limitationsIntended to resynchronize gastric slow waves but has variable symptom effects and uncertain benefit for gastroparesis

Transcend / Exilis / Implantable Gastric Stimulator (IGS) — device definition for obesity-targeted stimulators

Device examplesTranscend (Transneuronix/Medtronic) and Exilis — implantable gastric stimulators (IGS) developed for obesity treatment

System componentsPulse generator, external programmer, and gastric stimulation lead implanted laparoscopically with generator in subcutaneous tissue

Intended mechanismProposed to induce satiety by delaying gastric emptying to promote weight loss

Regulatory statusNot FDA approved for obesity in the U.S.; registered as investigational for obesity

Evidence/uncertaintiesMultiple unresolved issues: unclear mechanism, optimal stimulation patterns, lead placement, patient selection, and limited long-term evidence

DIAMOND (TANTALUS) device — device description for obesity/T2DM applications

Device nameDIAMOND (formerly TANTALUS) device

Electrode configurationThree pairs of bipolar electrodes: one pair on the gastric fundus and two pairs on the anterior and posterior antrum

ImplantationElectrodes implanted laparoscopically and connected to a pulse generator placed subcutaneously

Indication under investigationDeveloped for overweight/obese patients with type 2 diabetes to investigate effects on glycemic control and weight

Power/sourcePulse generator uses a rechargeable battery as an external power source and is programmed after implantation

Enterra Therapy — Enterra Therapy System and FDA HDE reference

Device/systemEnterra Therapy System — implanted gastric electrical stimulation device

Regulatory identifierFDA Humanitarian Device Exemption (HDE) approval: H990014

Intended HDE indicationChronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis (per FDA documentation)

Supporting FDA documentationFDA Approval Order and Summary of Safety and Probable Benefit for Enterra Therapy (H990014)